Total sales in the 340B drug pricing program reached $43.9 billion in 2021, a 15.6% increase over 2020 sales and more than 3.5 times above total sales in 2015 ($12.1 billion), according to federal data obtained by Drug Channels Institute under the Freedom of Information Act.
The institute is led by drug industry consultant Adam Fein, creator of the influential Drug Channels blog and a leading critic of hospitals that participate in 340B. For several years Fein has obtained the government’s most up-to-date 340B sales figures under FOIA and reported them in his blog. The U.S. Health Resources and Services Administration reports the same or slightly adjusted data months later in its annual budget requests to Congress. The figures come from Apexus, the 340B prime vendor, and do not include manufacturer direct sales to entities.
Total sales in the 340B drug pricing program reached $43.9 billion in 2021, a 15.6% increase over 2020 sales and more than 3.5 times above total sales in 2015 ($12.1 billion), according to federal data obtained by Drug Channels Institute under the Freedom of Information Act.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
